Speech-Language Pathologists in Mcpherson, KS Accepting Medicare

5 Speech-Language Pathologists found. Showing 1 - 5

Mr. Michael Craig Berger, SLP Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 1532 N Walnut St, Mcpherson, KS 67460 Phone: 620-480-9320    Fax: 620-210-6984

Mrs. Maryan Hulvey, M.S. Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1000 Hospital Dr, Mcpherson, KS 67460 Phone: 620-241-2250

Lisa Kay Stout, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 710 E Euclid St, Mcpherson, KS 67460 Phone: 620-680-0436

Kansas Speech Therapy Llc Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 1532 N Walnut St, Mcpherson, KS 67460 Phone: 620-480-9320    Fax: 620-210-6984

Mrs. Laura Ann Labertew, MS CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1000 Hospital Dr, Mcpherson, KS 67460 Phone: 620-242-2250

News Archive

Enrollment news to bank on: Obamacare is still here so it's time for coverage checkup

The open enrollment period begins in one week for 2018 marketplace coverage, but many consumers are confused about what to expect. No wonder!

$225,000 funding for promising epilepsy research

The Epilepsy Research Foundation (ERF), a unique joint venture of non-profit epilepsy organizations, and the Milken Family Foundation, a private philanthropic foundation, today announced two new grants recognizing promising epilepsy research in clinical development, totaling $225,000 in funding. The grant awards were announced by the Epilepsy Therapy Project and the Epilepsy Foundation, as well as the Milken Family Foundation, during the 7th Judith Hoyer Lecture in Epilepsy at the annual meeting of the American Epilepsy Society in Boston, MA.

Human monoclonal antibodies neutralize SARS-CoV-2 in an Fc-independent manner

Researchers from Israel recently isolated a set of SARS-CoV-2 neutralizing monoclonal antibodies from blood samples of patients with severe COVID-19. They were the first to show that transgenic K18-hACE2 mice infected with lethal doses of SARS-CoV-2 can be fully protected by administering antibodies even 3 days after infection

Funding requests are being accepted by BlueCross BlueShield of Tennessee Community Trust

The BlueCross BlueShield of Tennessee Community Trust is accepting funding requests for January-June 2019. The deadline to submit requests for funding cycle 1 of 2019 is Nov. 1, 2018.

New drugs have longer clinical development times despite faster FDA review

While the U.S. Food and Drug Administration Drug has quickened review and approval of new medicines, the complex nature of diseases for which new therapeutics are being developed has resulted in longer clinical development times, according to the Tufts Center for the Study of Drug Development.

Read more Medical News

› Verified 3 days ago